{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-028093","form_type":"8-K","ticker":"PCSA","cik":"0001533743","company_name":"Processa Pharmaceuticals, Inc.","filed_at":"2024-07-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.420289+00:00","generated_at":"2026-05-31T20:12:02.426509+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Processa appoints Russell Skibsted as CFO; James Stanker retires","bullets":["Russell Skibsted appointed CFO effective July 16, 2024; succeeds James Stanker who retired.","Skibsted brings 30 years of pharma finance experience; most recently CFO of Alimera Sciences.","Annual base salary $400,000; eligible for 35% target bonus and 28,000 RSUs upon goal achievement.","Stanker remains part-time employee during transition period."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-028093","json":"https://secwatch.observer/filing/0001493152-24-028093.json","markdown":"https://secwatch.observer/filing/0001493152-24-028093.md","text":"https://secwatch.observer/filing/0001493152-24-028093.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1533743/000149315224028093/0001493152-24-028093-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1533743/000149315224028093/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T20:12:02.426509+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0992fd920d","claim":"James Stanker resigned as Chief Financial Officer at Processa Pharmaceuticals, Inc..","evidence_excerpt":"by mutual agreement, James Stanker resigned as Chief Financial Officer of the Company, effective July 15, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533743/000149315224028093/0001493152-24-028093-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"e91bccbbd4","claim":"Russell Skibsted was appointed as Chief Financial Officer at Processa Pharmaceuticals, Inc..","evidence_excerpt":"announced the appointment of Mr. Russell Skibsted, Effective July 16, 2024 as its Chief Financial Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1533743/000149315224028093/0001493152-24-028093-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}